POLYMERIC DRUG DELIVERY SYSTEMS AND PROCESSES FOR PRODUCING SUCH SYSTEMS

• US 20120034306A1
• Filed: 04/19/2010
• Published: 02/09/2012
• Est. Priority Date: 04/17/2009
• Status: Abandoned Application

• Current Assignee: Albert H. Owens Jr, Stuart A. Grossman, Wayne C. Pollock
• Original Assignee: Albert H. Owens Jr, Stuart A. Grossman, Wayne C. Pollock
• Inventors: Pollock, Wayne C., Grossman, Stuart A., Owens, Albert H. Jr.
• Application Number:
  US13/264,813
• Publication Number:
  US 20120034306A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: B29C 45/00 Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor injection blow-moulding B29C49/06
• CPC Class Codes: B29L 2031/753 Medical equipment; Accessories therefor bloodbags, medical bags B29L2031/7148; artificial eyes B29L2011/0008

Abstract

The subject invention relates to implants for delivery of therapeutic agents such as opioids, and the manufacture and uses of such implants.

Claims

1. A subcutaneous delivery system comprising:

i) a biocompatible thermoplastic elastomer matrix,

ii) a therapeutic agent dispersed homogeneously in said matrix, and

iii) a biocompatible therapeutic agent impermeable thermoplastic polymer coating said matrix,

wherein said delivery system has a geometry such that there is an external coated wall and an internal uncoated wall forming an opening for release of said therapeutic agent, and the distance between the uncoated wall and the coated wall opposite the uncoated wall is substantially constant throughout the delivery system.

2. A subcutaneous delivery system as in claim 1, wherein said delivery system is cylindrical in shape.

3. A subcutaneous delivery system as in claim 1, wherein said matrix is a polyurethane matrix.

4. A subcutaneous delivery system as in claim 3, wherein said urethane matrix has an isocyanate as a hard segment, and a PEG, PPG or PTMEG glycol soft segment.

5. A subcutaneous delivery system as in claim 1, wherein said matrix is a copolyester matrix.

6. A subcutaneous delivery system as in claim 5, wherein said copolyester matrix has a polyester as a hard segment, and a PEG, PPG or PTMEG glycol soft segment.

7. A subcutaneous delivery system as in claim 1, wherein said matrix is a polyether block amide matrix.

8. A subcutaneous delivery system as in claim 7, wherein said polyether block amide matrix has a polyamide as a hard segment, and a PEG, PPG or PTMEG soft segment.

9. A subcutaneous delivery system as in claim 4, wherein the hard segment is 20-70% by weight of the matrix polymer with the remainder the soft segment.

10. A subcutaneous delivery system as in claim 4, wherein approximately 50% of the therapeutic agent is in solution with the soft segment of the matrix polymer while the remaining portion of the therapeutic agent is dispersed in the matrix and not in solution.

11. A subcutaneous delivery system as in claim 1, wherein said matrix and coating are non-biodegradable.

12. A subcutaneous delivery system as in claim 1, wherein said matrix and coating are biodegradable.

13. A subcutaneous delivery system as in claim 1, wherein said therapeutic agent is an opioid.

14. A subcutaneous delivery system as in claim 1, wherein said therapeutic agent is selected from the group consisting of hydromorphone, etorphine and dihydroetorphine.

15. A subcutaneous delivery system as in claim 1, wherein said therapeutic agent is an opioid and said coating is opioid impermeable.

16. A subcutaneous delivery system as in claim 1, wherein said matrix and coating comprise the same thermoplastic elastomer.

17. A subcutaneous delivery system as in claim 1, wherein said matrix and coating are polyurethane.

18. A subcutaneous delivery system as in claim 1, wherein said coating contains one or more inter-laminar diffusional drug barrier layers or films based on homopolymers of vinylidene chloride or copolymers of vinylidene chloride and vinyl chloride.

19. A subcutaneous delivery system as in claim 1, wherein said coating contains an adhesive tie coat between said coating and polymer matrix.

20. A subcutaneous delivery system as in claim 19, wherein said tie coat is an ethylenic anhydride either blended together with a different ethylinic anhydride or blended with an ethylenic copolymer, a copolyester, a Nylon copolymer or a thermoplastic polyurethane.

21. A subcutaneous delivery system as in claim 1, wherein said coating is two layers.

22. A subcutaneous delivery system as in claim 1, wherein said coating is three layers.

23. A subcutaneous delivery system as in claim 1, further comprising an outer coating having a second polymer matrix containing a second therapeutic agent.

24. A subcutaneous delivery system as in claim 21, wherein each coating is 24-48 microns thick.

27. A method of providing prolonged relief of pain in a mammal suffering from pain comprising subcutaneously administering the subcutaneous delivery system of claim 13.

25. A subcutaneous delivery system comprising

i) a thermoplastic elastomer matrix,

ii) a therapeutic agent embedded homogeneously in said matrix,

iii) a biocompatible therapeutic agent impermeable coating said matrix wherein said delivery system has a geometry such that there is an external coated wall and an internal uncoated wall forming an opening for release of said therapeutic agent, and the distance between the uncoated wall and the coated wall opposite the uncoated wall is substantially constant throughout the delivery system.

26. A subcutaneous delivery system comprising:

a biocompatible thermoplastic polyurethane matrix,

a therapeutic agent embedded homogeneously in said matrix, and

a biocompatible therapeutic agent impermeable thermoplastic polyurethane coating said matrix,

wherein said delivery system has a geometry such that there is an external coated wall and an internal uncoated wall forming an opening for release of said therapeutic agent, and the distance between the uncoated wall and the coated wall opposite the uncoated wall is substantially constant throughout the delivery system.

28. A method of producing a subcutaneous implant comprising the steps of:

i) forming a matrix polymer sheet of a first thermoplastic polymeric resin with a therapeutic agent dispersed in said matrix,

ii) die cutting said sheet to form polymer matrix, and

iii) coating said polymer matrix with a second thermoplastic polymeric resin which is impermeable to said therapeutic agent.

29. A method as in claim 28 wherein prior to step i) is the step of dry blending said first thermoplastic polymeric resin with a therapeutic agent, and step i) is by hot melt extrusion.

30. A method as in claim 28, wherein step i) is by solution casting.

31. A method as in claim 28 wherein after step iii) is the step of drying the coated polymer matrix.

32. A method as in claim 28 wherein after step iii) is the step of forming a channel in the coated polymer matrix.

33. A method as in claim 28 wherein said first thermoplastic polymeric resin is a resin blend.

34. A method as in claim 28 wherein said second thermoplastic polymeric resin is a resin blend.

35. A method as in claim 28, wherein said coating said matrix polymer is done by solution coating.

36. A method as in claim 28, wherein said coating said matrix polymer is done by hot melt extrusion.

37. A method as in claim 28, wherein said coating said polymer matrix is done by powder coating and then thermal fusion.

38. A method as in claim 28 wherein more than one coating is applied to said polymer matrix.

39. A method as in claim 28 wherein an outer coating is a second polymeric matrix containing a second therapeutic agent.

40. A method as in claim 28 wherein said first thermoplastic polymeric resin and said second thermoplastic polymeric resin are the same.

45. A method as in claim 28, wherein said first thermoplastic polymeric resin is extruded with a foaming agent.

41. A method of producing a subcutaneous implant delivery system comprising the steps of:

i) hot melt extrusion of a first thermoplastic polymeric elastomer resin with a therapeutic agent to form a polymer matrix in a cylindrical shape,

ii) powder coating and thermal fusing a second thermoplastic polymeric elastomer resin on said polymer matrix to form a therapeutic agent impermeable coating, and

iii) forming an uncoated channel in said implant.

42. A method of producing a subcutaneous implant delivery system having an uncoated central channel comprising the steps of:

co-extruding of a first thermoplastic polymeric elastomer resin and a therapeutic agent and a second thermoplastic polymeric elastomer resin into a multiple cavity die to form a coated polymer matrix.

43. A method as in claim 42 wherein said uncoated central channel is formed in the hot melt co-extrusion process.

44. A method as in claim 42 wherein said uncoated central channel is formed after the coated polymer matrix is formed.

46. A method of producing a subcutaneous implant comprising the steps of:

i) mixing a first thermoplastic elastomer polymeric resin with a polar solvent to form a polymer solution,

ii) adding an therapeutic agent to the solution,

iii) introducing the solution into a mold,

iv) drying the solution to form a matrix, and

v) coating the matrix with a second thermoplastic elastomer polymeric resin which is impermeable to the therapeutic agent.

47. A method as is claim 46 wherein said first thermoplastic elastomer polymeric resin is a polyurethane, copolyester or polyether block amid.

48. A method as is claim 46 wherein said second thermoplastic elastomer polymeric resin is a polyurethane, copolyester or polyether block amid.

49. A method as is claim 46 wherein said drying step is done in such a way as to eliminate the polar solvent.

50. A method as in claim 46 wherein the polar solvent is DMF or methylene chloride.

51. A method as in claim 46 wherein the therapeutic agent is hydromorphone.

52. A method as in claim 46 wherein said first thermoplastic polymeric elastomer resin and said second thermoplastic polymeric elastomer resin are the same.